CANF | Can-Fite BioPharma Ltd.
Category: Company
Quick infos Trade prices Volume: Market Cap: 24.47M Prev closed: 2.33 Open: 2.49 High: 2.8 Low: 2.36 52 week low: 1.08 52 week high: 4.95 Dividends: No Dividends Next ER: December 9, 2022 Before Market Opens
Company Profile Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.
Earnings History Date EPS / Forecast Revenue / Forecast March 23, 2023 November 25, 2022 -0.01 / -0.09613K / 300KBeat! August 25, 2022 -0.08 / -0.115409K / 409KBeat! May 26, 2022 - / -0.14205K / 133.33KBeat! March 24, 2022 -0.3 / -0.17204K / 266.67Kview more
Historical Data Date Price Open High Low Vol Change ER Mar 24, 2022 1.150 1.035 1.160
1.030
256.24K 12.75% Mar 23, 2022 1.020 1.030 1.060
1.020
152.42K -2.86% Mar 22, 2022 1.050 1.050 1.050
1.010
197.13K 5% Mar 21, 2022 1.000 1.040 1.050
0.990
172.95K -3.85% Mar 18, 2022 1.040 0.974 1.070
0.956
190.67K 6.08% Mar 17, 2022 0.980 0.957 1.000
0.950
91.86K 2.05% Mar 16, 2022 0.961 0.940 0.990
0.933
103.29K 0.07% Mar 15, 2022 0.960 0.953 0.986
0.901
274.39K 1.85% Mar 14, 2022 0.943 1.030 1.080
0.933
315.26K -2.82% Mar 11, 2022 0.970 0.970 1.000
0.960
183.95K 2.11% view more
NYSEAMERICAN
More profiles and info about the company News
Can-Fite Biopharma GAAP EPS of -$0.01, revenue of $0.61M seekingalpha.com Nov 25, 2022 8:03 pm Can-Fite Biopharma GAAP EPS of $0.00 beats by $0.09, revenue of $0.4M beats by $0.15M seekingalpha.com Aug 25, 2022 7:22 pm Can-Fite adds 18% as compassionate use of liver cancer therapy expands seekingalpha.com Aug 23, 2022 7:29 pm Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma finance.yahoo.com Mar 16, 2021 8:03 am Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol finance.yahoo.com Mar 5, 2021 8:03 am Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss finance.yahoo.com Feb 26, 2021 1:02 pm Can-Fite stock rises 23% as psoriasis drug beats placebo but lags behind Otezla in phase 3 trial seekingalpha.com Jun 29, 2022 8:40 pm Can-Fite Biopharma GAAP EPS of $0.00 beats by $0.14, revenue of $0.2M in-line seekingalpha.com May 26, 2022 7:32 pm Can-Fite reports positive data from preclinical trial of topical psoriasis treatment seekingalpha.com Apr 6, 2022 12:20 am Can-Fite Biopharma GAAP EPS of -$0.03, revenue of $0.85M seekingalpha.com Mar 24, 2022 9:21 pm Can-Fite stock rises 8% on notice of allowance of patent for liver drug seekingalpha.com Mar 14, 2022 8:56 pm Can-Fite delays topline data from late-stage psoriasis trial for lead asset seekingalpha.com Mar 8, 2022 8:30 pm Can-Fite begins enrollment in phase 2b trial of namodenoson to treat liver disease seekingalpha.com Jan 31, 2022 10:04 pm Can-Fite says Piclidenoson destroys pathological skin cells in vitro seekingalpha.com Jan 13, 2022 9:12 pm Can-Fite BioPharma to file for patents after new findings for liver cancer therapy seekingalpha.com Dec 29, 2021 8:43 pm Can-Fite announces exercise of warrants for cash proceeds of $10 million seekingalpha.com Dec 21, 2021 10:11 pm Can-Fite jumps 87% after namodenoson clears all lesions in Phase II liver cancer study seekingalpha.com Dec 20, 2021 10:29 pm This company doesn't provide a dividend.
Talk about Can-Fite BioPharma Ltd. below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis
